AIM ImmunoTech Inc. (AIM)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Annual

0 150K 300K 450K FY09: 111K FY10: 135K FY11: 161K FY12: 213K FY13: 150K FY14: 197K FY15: 133K FY16: 92K FY17: 437K FY18: 367K FY19: 140K FY20: 163K FY21: 135K FY22: 141K FY23: 202K FY24: 170K FY25: 88K FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Gross Profit Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Annual

-45M -30M -15M 0 15M 30M 45M FY09: -13.3M FY10: -16.4M FY11: -14.3M FY12: -20.3M FY13: -17.2M FY14: -19.1M FY15: -16.6M FY16: -13.8M FY17: -11.4M FY18: -11.5M FY19: -12.4M FY20: -15.2M FY21: -18.8M FY22: -19.9M FY23: -31.9M FY24: -19.8M FY25: -11.7M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Net Income Annual

-30M -20M -10M 0 10M 20M 30M FY09: -7.2M FY10: -13.1M FY11: -9M FY12: -17.4M FY13: -16.2M FY14: -17.4M FY15: -15.2M FY16: -7.5M FY17: -8.3M FY18: -9.8M FY19: -9.4M FY20: -14.4M FY21: -19.1M FY22: -19.4M FY23: -29M FY24: -17.3M FY25: -14M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Cost of Revenue Annual

0 700K 1.4M 2.1M FY09: 584K FY10: 1.3M FY11: 1M FY12: 2M FY13: 1.2M FY14: 1.3M FY15: 1.6M FY16: 1.1M FY17: 1.2M FY18: 884K FY19: 893K FY20: 806K FY21: 850K FY23: 42K FY24: 31K FY25: 128K FY10 FY12 FY14 FY16 FY18 FY20 FY23 FY25

Operating Cash Flow Annual

-24M -16M -8M 0 8M 16M 24M FY09: -9.3M FY10: -11.9M FY11: -10.1M FY12: -13.1M FY13: -16.8M FY14: -14M FY15: -16.1M FY16: -7.4M FY17: -7.9M FY18: -10.6M FY19: -9.1M FY20: -10.4M FY21: -14M FY22: -16.1M FY23: -21.3M FY24: -14.9M FY25: -11M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Free Cash Flow Annual

-21M -14M -7M 0 7M 14M 21M FY09: -9.6M FY10: -12.6M FY11: -11.9M FY12: -18.9M FY13: -17.7M FY14: -14.5M FY15: -16.3M FY16: -7.5M FY17: -8M FY18: -10.7M FY19: -9.1M FY20: -10.4M FY21: -14M FY22: -16.2M FY24: -14.9M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY24

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 20M 40M 60M FY22: 48M FY23: 48.6M FY24: 560.2K FY25: 1.6M FY22 FY23 FY24 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-21.00 -14.00 -7.00 0.00 7.00 14.00 21.00 Q4 '10: -0.09 Q1 '11: -0.06 Q2 '11: -0.07 Q3 '11: -0.07 Q4 '11: -0.07 Q1 '12: -0.08 Q2 '12: -0.08 Q3 '12: -0.11 Q4 '12: -0.12 Q1 '13: -0.12 Q2 '13: -0.13 Q3 '13: -0.11 Q4 '13: -0.10 Q1 '14: -0.10 Q2 '14: -0.10 Q3 '14: -0.09 Q4 '14: -1.11 Q1 '15: -1.11 Q2 '15: -1.10 Q3 '15: -1.26 Q4 '15: -0.37 Q1 '16: -0.45 Q2 '16: -0.49 Q3 '16: -0.44 Q4 '16: -0.33 Q1 '17: -0.34 Q2 '17: -0.36 Q3 '17: -0.27 Q4 '17: -0.29 Q1 '18: -0.25 Q2 '18: -2.55 Q3 '18: -5.38 Q4 '18: -6.64 Q1 '19: -9.48 Q2 '19: -8.17 Q3 '19: -6.43 Q4 '19: -2.58 Q1 '20: 0.11 Q2 '20: 1.07 Q3 '20: 2.12 Q4 '20: -0.50 Q1 '21: -0.36 Q2 '21: -0.37 Q3 '21: -0.37 Q4 '21: -0.40 Q1 '22: -0.40 Q2 '22: -0.38 Q3 '22: -0.43 Q4 '22: -0.40 Q1 '23: -0.40 Q2 '23: -0.40 Q3 '23: -0.43 Q4 '23: -0.60 Q1 '24: -0.64 Q2 '24: -3.54 Q3 '24: -9.38 Q4 '24: -19.04 Q1 '26: -3.24 Q2 '26: 0.01 Q2 '11 Q2 '13 Q2 '15 Q2 '17 Q2 '19 Q2 '21 Q2 '23 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.